Trials / Conditions / Primary Central Nervous System Lymphoma (PCNSL)

Primary Central Nervous System Lymphoma (PCNSL)

18 registered clinical trials studyying Primary Central Nervous System Lymphoma (PCNSL) — 12 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous NCT07523737	Beijing Tongren Hospital	Phase 2
Recruiting	PD-1 Inhibitor Combined With Rituximab, Methotrexate, and Orelabrutinib (PD-1i+RMO) for Newly Diagnosed PCNSL NCT07410520	The First Affiliated Hospital with Nanjing Medical University	Phase 2
Not Yet Recruiting	Relmacabtagene Autoleucel Combined With Autologous Hematopoietic Stem Cell Transplantation, Orelabrutinib, and NCT07198464	Zhengzhou University	N/A
Active Not Recruiting	A Study to Investigate the Pharmacokinetics of Tirabrutinib in Participants With Mild, Moderate, and Severe He NCT07198087	Ono Pharmaceutical Co., Ltd.	Phase 1
Recruiting	A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL) NCT07082868	Memorial Sloan Kettering Cancer Center	Phase 1
Recruiting	Metabolic and Immunomic Differential Analysis of Primary Central Nervous System Diffuse Large B-Cell Lymphoma NCT07188077	Ting YANG	—
Recruiting	Combination Regimen of Teniposide, PD-1 Monoclonal Antibody and Selinixor for Patients With Relapsed or Refrac NCT07074470	The First Affiliated Hospital of Soochow University	N/A
Not Yet Recruiting	High-dose Methotrexate Combined with Thiotepa and Zanubrutinib in the Treatment of Newly Diagnosed PCNSL (MTZ) NCT06646211	Sun Yat-sen University	Phase 2
Not Yet Recruiting	Real-World Evidence of Effectiveness and Safety of Tirabrutinib in Patients with Relapsed or Refractory Primar NCT06714370	Ono Pharmaceutical Co., Ltd.	—
Recruiting	Rituximab, Methotrexate, and Tepadina Induction Followed by Etoposide and Cytarabine Consolidation in Primary NCT06946407	FengYan Jin	N/A
Recruiting	A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies NCT05131022	Nurix Therapeutics, Inc.	Phase 1
Recruiting	High-Dose Gemcitabine, Busulfan, and Thiotepa Followed by ASCT in Primary Central Nervous System Lymphoma NCT07014943	Sichuan University	Phase 2
Recruiting	A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies NCT04830137	Nurix Therapeutics, Inc.	Phase 1
Active Not Recruiting	Rituximab, Acalabrutinib, and Durvalumab (RAD) in Primary CNS Lymphoma. NCT04688151	National Health Research Institutes, Taiwan	Phase 1
Completed	Nivolumab Maintenance in Newly Diagnosed PCNSL With Persistent CSF Circulating Tumor DNA After Completion of F NCT04401774	Memorial Sloan Kettering Cancer Center	Phase 2
Unknown	Mathematic Modeling at Micro and Macroscopic Level of Primary Central Nervous System Lymphomas (PCNSL) NCT04253496	Assistance Publique - Hôpitaux de Paris	—
Completed	Ibrutinib With Rituximab and Lenalidomide for Patients With Recurrent/Refractory Primary or Secondary Central NCT03703167	Memorial Sloan Kettering Cancer Center	Phase 1
Terminated	Neurotoxicity in Primary Central Nervous System Lymphoma (PCNSL): An International Observational Study of Cogn NCT00710151	OHSU Knight Cancer Institute	—